Arbutus Biopharma (ABUS) EBIT (2013 - 2026)

Arbutus Biopharma (ABUS) has reported EBIT for 14 consecutive years, with $168.9 million the latest figure, recorded in Q1 2026.

• Quarterly EBIT rose 757.26% year-over-year to $168.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.4 million (up 289.28% YoY) and the FY2025 annual result came in at -$38.2 million, up 50.0% from the prior year.
• EBIT rose to $168.9 million in Q1 2026 per ABUS's latest filing, from -$5.3 million in the prior quarter.
• Over the last five years, EBIT for ABUS reached as high as $168.9 million in Q1 2026 and fell as low as -$25.7 million in Q1 2025.
• A 5-year average of -$5.2 million and a median of -$17.8 million in 2022 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT tumbled 58.68% — and 2026, when it jumped 757.26%.
• Year by year, EBIT stood at -$22.6 million in 2022, then advanced by 8.04% to -$20.7 million in 2023, then jumped by 32.84% to -$13.9 million in 2024, then jumped by 62.03% to -$5.3 million in 2025, then soared by 3292.97% to $168.9 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $168.9 million, -$5.3 million, and -$8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.